May 30 2020
A proposal for a new clinical trial with a wide spectrum anti-viral called “isoquercetin” has been submitted to Health Canada by the Montreal Clinical Research Institute (MCRI)/Institut de Recherches Cliniques de Montréal (IRCM) under the leadership of Dr. Michel Chrétien. The trial targets patients hospitalized with mild to moderate COVID-19.
Dr Chrétien’s research team, in collaboration with the National Microbiology Laboratory in Winnipeg, has already demonstrated that isoquercetin is effective against the Ebola and Zika viruses in animals and against the SARS CoV-2 virus in vitro.
Dr. Jeremy Carver and the ICAV drug development team of Wendy Hill and Miklos Schulz are providing expert support for this study on the efficacy of this naturally-occurring compound that is present in most people’s diet, for example in onions.